Condition: Healthy Male Participants · Sponsor: Biocon Biologics UK PLC
This phase I study is to compare the pharmacokinetics (PK), immunogenicity, safety, and tolerability of Bmab3000 (test) and Herceptin Hylecta (reference) after a single subcutaneous (s.c.) dose in healthy male volunteers.
This description comes directly from the study's public registry record.
Dr Gursharan Singh, MBBS, PhD · 9650628534 · gursharan.singh@biocon.com
Rajesh CN · +919725466994 · rajesh.cn@biocon.com
Always discuss trial participation with your own doctor first.
| New Zealand Clinical Research (NZCR) | Christchurch, Main Building: 264 Antigua Street,, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07299955